Please use this identifier to cite or link to this item:
Title: Effects of losartan and diltiazem on blood pressure, insulin sensitivity, lipid profile and microalbuminuria in hypertensive type 2 diabetic patients
Authors: De Pablos Velasco, Pedro Luis 
Martínez Martín, Francisco Javier
UNESCO Clasification: 32 Ciencias médicas
3209 Farmacología
Keywords: Insulin sensitivity
Adis International Limited
Ambulatory blood pressure
Issue Date: 1998
Journal: Clinical Drug Investigation 
Abstract: Objective: To investigate the effect of losartan versus diltiazem on blood pressure, albuminuria, insulin sensitivity and lipid profile in a randomised, open study. p ]Patients: 40 type 2 diabetic patients (57 ± 12 years) from the Endocrinology clinic, with mild hypertension, persistent microalbuminuria and normal renal function, were randomly administered losartan 50 mg/day (n = 20) or diltiazem 300 mg/day (n = 20) for 12 weeks. After 1 month, hydrochlorothiazide 12.5mg was added if blood pressure was >130/85mm Hg. Outcome Measures: At baseline and after 3 months, plasma glucose, glycated haemoglobin (HbA1C), uric acid, lipid profile, albumin excretion rate and creatinine clearance were measured by routine methods. Insulin sensitivity was estimated by an insulin suppression test, and ambulatory blood pressure was monitored for 24 hours. Results: Mean systolic blood pressure decreased from 151 ± 15 to 133 ± 11mm Hg with losartan (p < 0.05) and from 153 ± 17 to 130 ± 18mm Hg with diltiazem (p < 0.05). Mean diastolic blood pressure decreased from 82 ± 12 to 74 ± 13mm Hg with losartan (p < 0.05) and from 85 ± 13 to 72 ± 16mm Hg with diltiazem (p < 0.05). Albuminuria decreased from 147 ± 56 to 121 ± 57 μg/min with losartan (p < 0.05) and from 143 ± 76 to 119 ± 49 μg/min with diltiazem (p < 0.05). Differences between the two treatments were not significant. Insulin sensitivity and lipid profile were not modified by any of the treatments and no adverse effects were reported. Conclusion: Both drugs were well tolerated and effectively reduced blood pressure and albuminuria, but did not modify insulin sensitivity or lipid profile.
ISSN: 1173-2563
DOI: 10.2165/00044011-199816050-00003
Source: Clinical Drug Investigation[ISSN 1173-2563],v. 16, p. 361-370
Appears in Collections:Artículos
Show full item record


checked on May 19, 2024

Page view(s)

checked on Jan 27, 2024

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.